Incorporação de esomeprazol em um hospital universitário: uma análise de custo-minimização: Série temática: Avaliação de Tecnologias em Saúde Hospitalar (ATS-H)

• Autor(a) principal: Garcia do Carmo Flausino, Tatiane
• Data de Publicação: 2024
• Outros Autores: Carrasco, Fábio Ricardo, Lauterbach, Gerhard da Paz, Figueiredo, Rosely Moralez
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: HU Revista (Online)
• Texto Completo: https://periodicos.ufjf.br/index.php/hurevista/article/view/42885
• topic: Costs and costs analysis; Analysis of the budgetary therapeutic advances; Omeprazole; Esomeprazole; Drug administration routes; Custos e Análise de Custo; Análise de Impacto Orçamentário de Avanços Terapêuticos; Omeprazol; Esomeprazol; Vias de Administração de Medicamentos

Introduction. Proton pump inhibitors (PPIs) are widely used in stress ulcer prophylaxis. Omeprazole is the most prescribed PPI in Brazil, but its conventional oral formulation is unsuitable for administration through a tube due to the risk of obstruction. The injectable presentation of omeprazole has a much higher cost than the oral formulation. Esomeprazole, composed of microgranules, is an alternative to injectable omeprazole as it can be administered through a tube and could potentially lead to a cost reduction. Objective. To analyze, through cost minimization, the financial impact of incorporating esomeprazole in a secondary university hospital. Material and Methods. A retrospective cross-sectional observational study was conducted to identify and analyze the consumption and cost related to the use of injectable omeprazole and esomeprazole in the years 2021 and 2022. Cost-minimization analysis was performed based on the collected data, to determine the financial impact after incorporating esomeprazole. Results. There was a 76.7% reduction in the consumption of injectable omeprazole in 2022. The cost-minimization analysis indicated a real cost of R$20,374.96 in 2022 for the 906 doses used during the period, of which 46.4% were injectable omeprazole and 53.6% were esomeprazole. Considering the scenario with exclusive therapy using injectable omeprazole, the simulated cost was R$41,252.05. The financial impact was R$-20,877.09, resulting in a resource savings of 50.6%. Conclusion. The incorporation of esomeprazole into the list of medications at a university hospital led to a significant cost reduction, resulting in over 50% savings in PPI consumption in the institution in 2022.